Sec Form 3 Filing - Sofer Uzi @ Alpha Tau Medical Ltd. - 2026-03-18

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Sofer Uzi 2. Issuer Name and Ticker or Trading Symbol Alpha Tau Medical Ltd. [ DRTS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) C/O ALPHA TAU MEDICAL LTD. 3. Date of Earliest Transaction (MM/DD/YY) 03/18/2026 (Street) JERUSALEM9777605 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 1,250,941 D Restricted Share Units ( 1 ) 4,680 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Options ( 2 ) $ 1.1 01/01/2017 02/21/2027 Ordinary Shares 54,318 D Options ( 2 ) $ 4.42 03/01/2019 11/26/2028 Ordinary Shares 54,318 D Options ( 2 ) $ 11.5 06/07/2022 08/08/2031 Ordinary Shares 174,770 D Options ( 2 ) $ 10.92 11/02/2022 03/21/2032 Ordinary Shares 8,945 D Options ( 2 ) $ 10.92 06/07/2022 03/21/2032 Ordinary Shares 229,089 D Options ( 2 ) $ 7.19 11/02/2022 06/02/2032 Ordinary Shares 10,657 D Options ( 2 ) $ 7.19 06/07/2022 06/02/2032 Ordinary Shares 250,933 D Options ( 2 ) $ 3.28 01/01/2024 03/09/2033 Ordinary Shares 46,905 D Options ( 2 ) $ 3.57 04/01/2023 03/09/2033 Ordinary Shares 1,102,653 D Options ( 2 ) $ 2.98 12/17/2024 03/07/2034 Ordinary Shares 43,257 D Options ( 2 ) $ 3.48 04/01/2024 03/07/2034 Ordinary Shares 763,843 D Options ( 2 ) $ 4.05 06/17/2025 01/22/2035 Ordinary Shares 24,460 D Options ( 2 ) $ 3.07 04/01/2025 01/22/2035 Ordinary Shares 674,238 D Options ( 3 ) $ 6.41 ( 3 ) 03/09/2036 Ordinary Shares 15,527 D Options ( 4 ) $ 7.32 ( 4 ) 03/09/2036 Ordinary Shares 396,680 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Sofer Uzi C/O ALPHA TAU MEDICAL LTD. JERUSALEM9777605 X Chief Executive Officer Signatures /s/ Uzi Sofer 03/18/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service. ( 2 )These are options to acquire ordinary shares, which have fully vested as of the date hereof. ( 3 )These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service. ( 4 )These are options to acquire ordinary shares, which options which vest in quarterly equal installments for a period of four years commencing January 1, 2026, subject to the Reporting Person's continued service.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.